Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women

JAMA

Volumn 281, Issue 2, 1999, Pages 151-157

  Culnane, Mary ^a   Fowler, MaryGlenn ^b   Lee, Sophia S ^b   McSherry, George ^b   Brady, Michael ^b   O'Donnell, Karen ^b   Mofenson, Lynne ^b   Gortmaker, Steven L ^b   Shapiro, David E ^b   Scott, Gwendolyn ^b   Jimenez, Eleanor ^b   Moore, Ellen C ^b   Diaz, Clemente ^b   Flynn, Patricia M ^b   Cunningham, Bethann ^b   Oleske, James ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ZIDOVUDINE;

ADULT; ARTICLE; CARDIOMYOPATHY; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MONITORING; DRUG SAFETY; FEMALE; FETUS OUTCOME; FOLLOW UP; GROWTH RATE; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MATERNAL TREATMENT; MULTICENTER STUDY; PRENATAL DRUG EXPOSURE; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TERATOGENICITY; VIRUS TRANSMISSION;

EID: 0033550472     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.281.2.151     Document Type: Article

References (21)

1. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331:1173-1180.
2. Centers for Disease Control and Prevention. Update: perinatally acquired HIV/AIDS - United States, 1997. MMWR Morb Mortal Wkly Rep. 1997;46: 1086-1092.
3. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med. 1990;322:941-949.
4. McKinney RE, Maha MA, Connor EM, et al. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. N Engl J Med. 1991;324:1018-1025.
5. Ayers KM, Clive D, Tucker WE Jr, Hajian G, de Miranda P. Nonclinical toxicology studies with zidovudine: genetic toxicity and carcinogenicity bioassays in mice and rats. Fundam Appl Toxicol. 1996;32:148-158.
6. The European Collaborative Study. Age-related standards for T lymphocyte subsets based on uninfected children born to human immunodeficiency virus 1-infected women. Pediatr Infect Dis J. 1992;11: 1018-1026.
7. McKinney RE, Wilfert CM. Lymphocyte subsets in children younger than 2 years old: normal values in a population at risk for human immunodeficiency virus infection and diagnostic and prognostic application to infected children. Pediatr Infect Dis J. 1992;11:639-644.
8. Bayley N. The Bayley Scales of Infant Development. San Antonio, Tex: The Psychological Corp; 1993.
9. McCarthy D. The McCarthy Scales of Children's Abilities. San Antonio, Tex: The Psychological Corp; 1972.
10. Wei LJ, Johnson WE. Combining dependent tests with incomplete repeated measurements. Biometrika. 1985;72:359-364.
11. Dibley MJ, Goldsby JB, Staehling NW, et al. Development of normalized curves for the international growth reference: historical and technical considerations. Am J Clin Nutr. 1987;46:736-748.
12. Roche AF, Himes JH. Incremental growth charts. Am J Clin Nutr. 1980;33:2041-2052.
13. Fiscus SA, Adimora AA, Schoenbach VJ, et al. Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties. JAMA. 1996;275:1483-1488.
14. Mayaux MJ, Teglas JP, Mandelbrot L, et al. Acceptability and impact of zidovudine for prevention of mother-to-child human immunodeficiency virus-1 transmission in France. J Pediatr. 1997;131:857-862.
15. Confronting AIDS: Public Priorities in a Global Epidemic A World Bank Policy Research Report. New York, NY: Oxford University Press Inc; 1997.
16. Sperling RS, Shapiro DE, McSherry GD, et al. Safety of the maternal-infant zidovudine regimen utilized in Pediatric AIDS Clinical Trial Group 076 study. AIDS. 1998;12:1805-1813.
17. Antiretroviral Pregnancy Registry for Didanosine, Lamivudine, Saquinavir, Stavudine, Zalcitabine, Zidovudine, Crixivan: Interim Report, 1 January 1989 Through 30 December 1997. Research Triangle Park, NC: Bristol Myers Squibb Co, Glaxo-Wellcome, Hoffman-LaRoche Inc, Merck & Co Inc; 1997.
18. Hanson C, Cooper E, Antonelli T, et al. Lack of tumors in infants with perinatal HIV exposure and fetal/ neonatal exposure to zidovudine. In: Proceedings of the National Conference on Women and HIV; May 4-7, 1997; Pasadena, Calif. Abstract 304.3.
19. Ayers KM, Torrey CE, Reynolds DJ. A transplacental carcinogenicity bioassay in CD-1 mice with zidovudine. Fundam Appl Toxicol. 1997;38:195-198.
20. Olivero OA, Anderson LM, Diwan BA, et al. Transplacental effects of 3'-azido-2',3'-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst. 1997;89:1602-1608.
21. Centers for Disease Control and Prevention. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR Morb Mortal Wkly Rep. 1998;47:2-26.